InflaRx N.V. (IFRX) stock
IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.01 (+0.85%)
Close on Nov 16, 2026Market cap $85.31MP/E –Yield –
InflaRx cash
Cash and short-term investments held at the end of each period.
InflaRx's cash was €16.02M at Dec 31, 2025. For fiscal 2025 it was €16.02M, down 12.8% from the year before. Over ten years it grew 17.1% a year on average. The highest annual figure on record is €123.28M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €16.02M | -12.8% |
| FY2024 | Dec 31, 2024 | €18.38M | +43.9% |
| FY2023 | Dec 31, 2023 | €12.77M | -21.5% |
| FY2022 | Dec 31, 2022 | €16.27M | -38.0% |
| FY2021 | Dec 31, 2021 | €26.25M | +1.1% |
| FY2020 | Dec 31, 2020 | €25.97M | -21.6% |
| FY2019 | Dec 31, 2019 | €33.13M | -40.2% |
| FY2018 | Dec 31, 2018 | €55.39M | -55.1% |
| FY2017 | Dec 31, 2017 | €123.28M | +323.4% |
| FY2016 | Dec 31, 2016 | €29.12M | +781.8% |
| FY2015 | Dec 31, 2015 | €3.30M | -50.1% |
| FY2014 | Dec 31, 2014 | €6.62M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | €16.02M | +25.5% |
| Q2 FY2025 | Jun 30, 2025 | €13.00M | -33.4% |
| Q4 FY2024 | Dec 31, 2024 | €18.38M | +13.0% |
| Q2 FY2024 | Jun 30, 2024 | €19.15M | +24.2% |
| Q4 FY2023 | Dec 31, 2023 | €12.77M | -51.4% |
| Q2 FY2023 | Jun 30, 2023 | €19.52M | -73.0% |
| Q4 FY2022 | Dec 31, 2022 | €16.27M | -37.4% |
| Q2 FY2022 | Jun 30, 2022 | €15.42M | -53.5% |
| Q4 FY2021 | Dec 31, 2021 | €26.25M | -51.4% |
| Q2 FY2021 | Jun 30, 2021 | €72.36M | +30.6% |
| Q4 FY2020 | Dec 31, 2020 | €25.97M | -83.4% |
| Q4 FY2019 | Dec 31, 2019 | €33.13M | -73.1% |
| Q2 FY2019 | Jun 30, 2019 | €54.06M | +85.7% |
| Q4 FY2018 | Dec 31, 2018 | €55.39M | +1577.4% |
| Q2 FY2018 | Jun 30, 2018 | €156.07M | +2256.8% |
| Q4 FY2017 | Dec 31, 2017 | €123.28M | – |
| Q4 FY2016 | Dec 31, 2016 | €29.12M | – |
| Q4 FY2015 | Dec 31, 2015 | €3.30M | – |
| Q4 FY2014 | Dec 31, 2014 | €6.62M | – |
See a number that looks wrong?